ArticleCancer discovery2017
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 518 papers.
0numbers the graph read from it
0cells of the map it votes in
518citing papers in PubMed
23.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
518 citing papers in PubMed, 730 citations in OpenAlex.
- Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).Cell reports. Medicine · 2024Trial
- Dedifferentiation in endometrial cancer is associated with HLA-I silencing that may be restored by IFN-γ.The Journal of pathology · 2026Article
- Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy.Molecular oncology · 2026Article
- The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation.Biomarker research · 2026Review
- TCASIA: an integrative atlas linking alternative splicing landscapes for cancer immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation.International journal of molecular sciences · 2026Review
- Antigen-Presentation Competence in Gynecologic Cancers: Mechanisms, Evidence and Translational Priorities.Cells · 2026Review
- Targeting the Tumor Microenvironment Network to Overcome Immunotherapy Resistance in Non-Small Cell Lung Cancer: Mechanisms to Clinical Translation.Cancer medicine · 2026Review
- Evidence-steered medicine in oncology: network-aware micro-combinations that safeguard standard of care and potentially improve benefit-risk.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Re-expression of MHC-I to treat CNS cancers.Oncotarget · 2026Review
- Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects.Signal transduction and targeted therapy · 2026Review
- Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review
- Effect of Tertiary Lymphoid Structures on Immune Cell Infiltration in the Tumor Microenvironment and Prognosis in Lung Adenocarcinoma.Cancer medicine · 2026Article
- Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Immunotherapy in Gynecologic Cancers: Current Evidence, Biomarker-Driven Practice, and Future Directions.Cancers · 2026Review
- Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.Research square · 2026Article
- The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma.Journal of advanced research · 2026Article
458 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 2 countries.
Scott GettingerDepartment of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu scott.gettinger@yale.edu.
Jungmin ChoiDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.
Katherine HastingsYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Anna TruiniYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Ila DatarDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Ryan SowellDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.
Anna WurtzYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Weilai DongDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.
Guoping CaiDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Mary Ann MelnickYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Victor Y DuDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.
Joseph SchlessingerYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Sarah B GoldbergDepartment of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut.
Anne ChiangDepartment of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut.
Miguel F SanmamedDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.
Ignacio MeleroCIMA and Clinica Universidad de Navarra, Pamplona, Spain.
Jackeline AgorretaCIMA and Clinica Universidad de Navarra, Pamplona, Spain.
Luis M MontuengaCIMA and Clinica Universidad de Navarra, Pamplona, Spain.
Richard LiftonDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.
Soldano FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Paula KavathasYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
David L RimmYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Susan M KaechYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Kurt SchalperDepartment of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut.
Roy S HerbstDepartment of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut.
Katerina PolitiDepartment of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu scott.gettinger@yale.edu.
Yale Cancer Center · USYale University · USClinica Universidad de Navarra · ESMassachusetts General Hospital · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Rajni Mehta · 1985 to 2026
$85.0MYale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1MIMMUNOHEMATOLOGY/TRANSFUSION MEDICINE RESEARCH TRAININGT32HL007974 · NHLBI · YALE UNIVERSITY · PI JEANNE E HENDRICKSON, Diane S Krause · 2001 to 2026
$8.1MTargeting the Immune System in Mouse Models of Lung AdenocarcinomaR01CA195720 · NCI · YALE UNIVERSITY · PI KAECH, SUSAN M, POLITI, KATERINA ABIGAIL · 2015 to 2017
$1.8MMechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Lung AdenocarcinomaF32CA210516 · NCI · YALE UNIVERSITY · PI HASTINGS, KATHERINE RENEE AMATO · 2017 to 2018
$116kNCATS NIH HHS UL1 TR001863NCI NIH HHS F32 CA210516NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA195720NHLBI NIH HHS T32 HL007974
Abstract
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy-number changes were not detected in our cohort. In one case, we found acquired homozygous loss of
Indexed as
Drug Resistance, NeoplasmGene Expression Regulation, NeoplasticHistocompatibility Antigens Class IHumansLung NeoplasmsSignal TransductionHistocompatibility Antigens Class I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.